nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
1 |
Aspirin in the treatment and prevention of cardiovascular disease: Current perspectives and future directions
|
Hennekens, Charles H. |
|
2007 |
9 |
5 |
p. 409-416 |
artikel |
2 |
Clopidogrel and risk for acute coronary events
|
Mood, Girish R. |
|
2007 |
9 |
5 |
p. 401-408 |
artikel |
3 |
Does it matter how you lower blood pressure in patients with uncomplicated hypertension? Weighing the evidence
|
Duprez, Daniel A. |
|
2007 |
9 |
5 |
p. 352-358 |
artikel |
4 |
Does it matter whether or not a lipid-lowering agent inhibits Rho kinase?
|
Liao, James K. |
|
2007 |
9 |
5 |
p. 384-388 |
artikel |
5 |
Dyslipidemia in South Asian patients
|
Enas, Enas A. |
|
2007 |
9 |
5 |
p. 367-374 |
artikel |
6 |
Evidence-based treatment of unprotected left main disease: A critical review of the literature
|
Sharis, Peter |
|
2007 |
9 |
5 |
p. 397-400 |
artikel |
7 |
Myeloperoxidase and inflammatory proteins: Pathways for generating dysfunctional high-density lipoprotein in humans
|
Vaisar, Tomáš |
|
2007 |
9 |
5 |
p. 417-424 |
artikel |
8 |
Rimonabant: The role of endocannabinoid type 1 receptor antagonism in modulating the weight and lipid profile of obese patients
|
Dibble, Christopher T. |
|
2007 |
9 |
5 |
p. 359-366 |
artikel |
9 |
Should hyperhomocysteinemia be treated in patients with atherosclerotic disease?
|
Maron, Bradley A. |
|
2007 |
9 |
5 |
p. 375-383 |
artikel |
10 |
SPARCL: The glimmer of statins for stroke risk reduction
|
Armani, Annemarie |
|
2007 |
9 |
5 |
p. 347-351 |
artikel |
11 |
Statin myopathy: Incidence, risk factors, and pathophysiology
|
Sewright, Kimberly A. |
|
2007 |
9 |
5 |
p. 389-396 |
artikel |
12 |
The COURAGE trial: Establishing the Therapeutic Legitimacy of Aggressive Risk Factor Management in Patients with Stable Coronary Artery Disease as an Alternative to Percutaneous Coronary Intervention
|
Toth, Peter P. |
|
2007 |
9 |
5 |
p. 345-346 |
artikel |
13 |
Web alert
|
|
|
2007 |
9 |
5 |
p. 341 |
artikel |